Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial CarcinomaZacks Investment Research • 09/04/24
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024Business Wire • 09/04/24
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular EdemaBusiness Wire • 09/04/24
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall StreetBenzinga • 09/03/24
European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in AdultsBusiness Wire • 09/03/24
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing DataZacks Investment Research • 08/30/24
Merck Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)Business Wire • 08/29/24
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire • 08/29/24
Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?Zacks Investment Research • 08/27/24
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential ThrombocythemiaBusiness Wire • 08/27/24
The Zacks Analyst Blog Costco, Merck & Co., Linde, Hamilton Beach Brands and Armanino Foods of DistinctionZacks Investment Research • 08/26/24
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-IIIBusiness Wire • 08/26/24